Expression and Significance of C-myc and Skp2 in Triple-Negative Breast Cancer_West China Medical Journal

Authors：

YIN Xiaoling ^1,2 , QIN Jingyun ¹ ,  WANG Lei ³ , SHI Zhimin ³ , NIU Lihui. ¹

1. Department of Thoracic Surgery; 2. Department of Ophthalmology, Handan Central Hosptial, Handan, Hebei 056001, P. R. China; 3. Department of Pathology Staffroom, Medical College of Hebei University of Engineering, Handan, Hebei 056004, P. R. China;

Corresponding?author：

WANG Lei, Email: ll5905724@126.com

Keywords：

三陰乳腺癌; C-myc; Skp2; 免疫組織化學

DOI：

10.7507/1002-0179.20130530

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

目的　檢測三陰乳腺癌（TNBC）組織中C-myc和Skp2的表達情況及其意義。方法　選取2008年1月－2011年12月手術切除的TNBC標本56例，采用免疫組織化學鏈霉素抗生物素蛋白-過氧化物酶連結法檢測它們和30例癌旁正常乳腺組織中C-myc和Skp2的表達情況。結果　TNBC組織中C-myc和Skp2表達定位于細胞核，其表達率分別為57.14%（32/56）和58.93%（33/56），明顯高于癌旁正常組織（P＜0.05）；56例TNBC組織中，C-myc和Skp2蛋白在組織學分級Ⅲ級表達率高于Ⅰ+Ⅱ級（P＜0.05）；C-myc和Skp2的病理分期Ⅲ期的表達率高于Ⅰ-Ⅱ期（P＜0.05）；表達率高低與腋窩有無淋巴結轉移有關（P＜0.05），而與病理組織類型無關（P＞0.05）；相關性分析顯示，C-myc和Skp2二者之間呈正相關（P＜0.05）。結論　C-myc和Skp2在TNBC中呈明顯高表達，與TNBC的發生、發展和轉移密切相關。

Citation： YIN Xiaoling,QIN Jingyun,WANG Lei,SHI Zhimin,NIU Lihui.. Expression and Significance of C-myc and Skp2 in Triple-Negative Breast Cancer. West China Medical Journal, 2013, 28(11): 1675-1677. doi: 10.7507/1002-0179.20130530 Copy

1.	段學寧, 張弛, 徐玲. 乳腺癌新輔助治療個體化管理[J]. 中國實用外科雜志, 2011, 31(10): 926-928.
2.	龔西騟, 丁華野. 乳腺病理學[M]. 北京: 人民衛生出版社, 2009: 426-430.
3.	儲君. 三陰性乳腺癌的臨床病理特征及預后因素分析[J]. 現代腫瘤醫學, 2011, 19(5): 921-924.
4.	Elston D, Eliis KI. Pathological prognostic factors in breast cancer I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up[J]. Histopathology, 1997, 19(5): 403.
5.	Parenti A, Leo G, Porzionato A, et al. Expression of survivin, p53, and caspase 3 in Barrett’s esophagus carcinogenesis[J]. Hum Pathol, 2006, 37(1): 16-22.
6.	王蕾, 何妍, 李希芳, 等. 大腸癌E2F -1、CyclinD1的表達及其意義[J]. 武警醫學, 2011, 22(11): 935-937, 942.
7.	Hu F, Gartenhaus RB, Zhao XF, et al. c-Myc and E2F1 drive PBK/TOPK expression in high-grade malignant lymphomas[J]. Leuk Res, 2013, 37(4): 447-454.
8.	Shachaf CM, Felsher DW. Tumor dormancy and MYC inactivation: pushing cancer to the brink of normalcy[J]. Cancer Res, 2005, 65(11): 4471-4474.
9.	Duangmano S, Dakeng S, Jiratchariyakul W, et al. Antiproliferative effects of cucurbitacin B in breast cancer cells: Down-Regulation of the c-Myc/hTERT/telomerase pathway and obstruction of the cell cycle[J]. Int J Mol Sci, 2010, 11(12): 5323-5338.
10.	Xu AG, Li SG, Liu JH, et al. Function of apoptosis and expression of the proteins Bcl-2, p53 and C-myc in the development of gastric cancer[J]. World J Gastroenterol, 2001, 7(3): 403-406.
11.	Assoian RK, Yung Y. A reciprocal relationship between Rb and Skp2: implications for restriction point control, signal transduction to the cell cycle and cancer[J]. Cell Cycle, 2008, 7(1): 24-27.
12.	Takanami I. The prognostic value of overexpression of Skp2 mRNA in non-small cell lung cancer[J]. Oncol Rep, 2005, 13(4): 727-731.
13.	許朝, 姜藻. PI3K/Akt信號通路抑制劑對胃癌細胞SGC7901中Skp2和NAG-1表達的影響及其效應[J]. 中國全科醫學, 2010, 13(14): 1557-1560.
14.	宋坤, 劉慧, 范欽和. Skp2和p27在乳腺癌分子亞型中的表達及與基底樣型乳腺癌的關系[J]. 診斷病理學雜志, 2010, 17(6): 411-415.
15.	Gao D, Inuzuka H, Tseng A, et al. Akt finds its new path to regulate cell cycle through modulating Skp2 activity and its destruction by APC/Cdh1[J]. Cell Div, 2009, 4(1): 11.

1. 　段學寧, 張弛, 徐玲. 乳腺癌新輔助治療個體化管理[J]. 中國實用外科雜志, 2011, 31(10): 926-928.
2. 　龔西騟, 丁華野. 乳腺病理學[M]. 北京: 人民衛生出版社, 2009: 426-430.
3. 　儲君. 三陰性乳腺癌的臨床病理特征及預后因素分析[J]. 現代腫瘤醫學, 2011, 19(5): 921-924.
4. 　Elston D, Eliis KI. Pathological prognostic factors in breast cancer I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up[J]. Histopathology, 1997, 19(5): 403.
5. 　Parenti A, Leo G, Porzionato A, et al. Expression of survivin, p53, and caspase 3 in Barrett’s esophagus carcinogenesis[J]. Hum Pathol, 2006, 37(1): 16-22.
6. 　王蕾, 何妍, 李希芳, 等. 大腸癌E2F -1、CyclinD1的表達及其意義[J]. 武警醫學, 2011, 22(11): 935-937, 942.
7. 　Hu F, Gartenhaus RB, Zhao XF, et al. c-Myc and E2F1 drive PBK/TOPK expression in high-grade malignant lymphomas[J]. Leuk Res, 2013, 37(4): 447-454.
8. 　Shachaf CM, Felsher DW. Tumor dormancy and MYC inactivation: pushing cancer to the brink of normalcy[J]. Cancer Res, 2005, 65(11): 4471-4474.
9. 　Duangmano S, Dakeng S, Jiratchariyakul W, et al. Antiproliferative effects of cucurbitacin B in breast cancer cells: Down-Regulation of the c-Myc/hTERT/telomerase pathway and obstruction of the cell cycle[J]. Int J Mol Sci, 2010, 11(12): 5323-5338.
10. 　Xu AG, Li SG, Liu JH, et al. Function of apoptosis and expression of the proteins Bcl-2, p53 and C-myc in the development of gastric cancer[J]. World J Gastroenterol, 2001, 7(3): 403-406.
11. 　Assoian RK, Yung Y. A reciprocal relationship between Rb and Skp2: implications for restriction point control, signal transduction to the cell cycle and cancer[J]. Cell Cycle, 2008, 7(1): 24-27.
12. 　Takanami I. The prognostic value of overexpression of Skp2 mRNA in non-small cell lung cancer[J]. Oncol Rep, 2005, 13(4): 727-731.
13. 　許朝, 姜藻. PI3K/Akt信號通路抑制劑對胃癌細胞SGC7901中Skp2和NAG-1表達的影響及其效應[J]. 中國全科醫學, 2010, 13(14): 1557-1560.
14. 　宋坤, 劉慧, 范欽和. Skp2和p27在乳腺癌分子亞型中的表達及與基底樣型乳腺癌的關系[J]. 診斷病理學雜志, 2010, 17(6): 411-415.
15. 　Gao D, Inuzuka H, Tseng A, et al. Akt finds its new path to regulate cell cycle through modulating Skp2 activity and its destruction by APC/Cdh1[J]. Cell Div, 2009, 4(1): 11.

West China Medical Journal

Expression and Significance of C-myc and Skp2 in Triple-Negative Breast Cancer

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content